Triomune (Lamivudine 150mg + Stavudine 30mg + Nevirapine 200mg)

What is Triomune (Lamivudine 150mg + Stavudine 30mg + Nevirapine 200mg)?

Triomune (Lamivudine 150mg + Stavudine 30mg + Nevirapine 200mg) is a fixed-dose combination antiretroviral medication used in the management of HIV-1 infection. It combines three essential drugs—lamivudine, stavudine, and nevirapine—into a single tablet to simplify treatment regimens, especially in resource-limited settings. Manufactured as a generic alternative to branded ART therapies, Triomune helps suppress viral replication, maintain immune function, and reduce HIV transmission risk when used consistently as prescribed.

Key features

• Triple therapy — Combines nucleoside and non-nucleoside reverse transcriptase inhibitors for broad antiviral action.
• Dosing convenience — Single tablet reduces pill burden, improving adherence in daily HIV treatment.
• WHO-recommended — Historically included in guidelines for first-line HIV therapy in low-income countries.
• Cost-effective — Offers an affordable alternative to branded regimens where access is limited.
• Stable formulation — Designed for long shelf life and storage without refrigeration.
• Oral tablet — Taken twice daily with or without food, depending on clinical guidance.
• Generic origin — Produced under licensing agreements to increase global HIV treatment access.

Who is Triomune (Lamivudine 150mg + Stavudine 30mg + Nevirapine 200mg) for?

This medication is intended for adults and select pediatric patients with HIV-1 infection who are beginning antiretroviral therapy, particularly in regions where stavudine-based regimens are still utilized. It is prescribed under strict medical supervision due to potential side effects and drug interactions. Not suitable for patients with known hypersensitivity to any component.

How does Triomune (Lamivudine 150mg + Stavudine 30mg + Nevirapine 200mg) compare?

Compared to modern integrase inhibitor-based regimens, Triomune has a higher risk of long-term side effects like peripheral neuropathy and lipoatrophy due to stavudine. However, it remains a viable option in areas with limited access to newer drugs. It is less expensive than newer fixed-dose combinations but requires more frequent monitoring. While effective, it is generally considered a legacy regimen in updated treatment standards.